Markets

OncoMed Pharmaceuticals Slumps: OMED Plunges 10.2% in Session - Tale of the Tape

OncoMed Pharmaceuticals, Inc. ( OMED ) saw a big move last session, as the company's shares fell by about 10% on the day. The move came on pretty good volume too with far more shares changing hands than in a normal session. This continues the recent downtrend for OMED, as the stock is now down 25.2% since July 23.

This development-stage biotechnology company has seen a flat track record when it comes to current year estimate revisions over the past few weeks and the consensus for loss hasn't been in a trend either. This recent price action is discouraging, so make sure to keep a close watch of this firm in the near future, and especially on earnings estimates following the recent slump.

OMED currently has a Zacks Rank #5 (Strong Sell).

Some better-ranked stocks in the Med-Biomed/Generic industry include Actelion Ltd. ( ALIOF ), Cambrex Corporation. ( CBM ) and China Biologic Products, Inc. ( CBPO ). All these stocks hold a Zacks Rank #1 (Strong Buy).

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days . Click to get this free report >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

ONCOMED PHARMA (OMED): Free Stock Analysis Report

ACTELION LTD (ALIOF): Get Free Report

CAMBREX CORP (CBM): Free Stock Analysis Report

CHINA BIOLOGIC (CBPO): Get Free Report

To read this article on Zacks.com click here.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

CBPO

Other Topics

Investing Stocks

Latest Markets Videos

    Zacks

    Zacks is the leading investment research firm focusing on stock research, analysis and recommendations. In 1978, our founder discovered the power of earnings estimate revisions to enable profitable investment decisions. Today, that discovery is still the heart of the Zacks Rank. A wealth of resources for individual investors is available at www.zacks.com.

    Learn More